Marina Aslanyan Takes the Helm as CEO of Cadara, Driving Innovation in Healthcare Technology

Cadara Welcomes Marina Aslanyan as CEO

Cadara, previously known as National Care Systems, has ushered in a new era with the appointment of Marina Aslanyan as Chief Executive Officer. Known for her extensive background in healthcare technology, Aslanyan is set to lead the company during a transformative time as it expands its services and technology offerings.

Aslanyan's arrival is not just a change at the top; it signifies Cadara's commitment to innovation in the post-acute care sector. Under her leadership, the company aims to enhance its technology platform and further its strategic goals. Cadara, supported by Sheridan Capital Partners since late 2025, is accelerating its investments in artificial intelligence and next-generation technologies. As the industry faces increasing operational challenges, Cadara aims to provide solutions that meet the evolving needs of healthcare providers.

With over 25 years of experience, Aslanyan has a proven track record in executive leadership within the enterprise software and healthcare technology sectors. She previously served as CEO of SmartLinx, where she drove advancements in workforce management technology specifically for skilled nursing and post-acute care organizations across North America. Her past roles include important leadership positions at Altitude Strategic Consulting, Sparta Systems, and PricewaterhouseCoopers, which provide her with a broad and robust perspective on the healthcare market.

Jacob Greenberg, Partner at Sheridan Capital Partners, expressed confidence in Aslanyan’s ability to enhance Cadara's already solid foundation, saying, "Marina's leadership and expertise will be vital as we take the next steps forward." As part of her vision, Aslanyan emphasizes the importance of customer success and relationships built on trust, a sentiment echoed by David Klein, Founder of National Care Systems. Klein stated that Aslanyan embodies the company's longstanding commitment to its customers—"when our customers succeed, we succeed."

In her new role, Aslanyan will concentrate on Cadara’s long-term strategy, innovation in product offerings, and the overall success of the customer base. She assured stakeholders that her vision aligns with the current challenges faced by post-acute organizations, emphasizing that they are under pressure to do more with fewer resources. Cadara intends to assist these organizations through tailored innovations and trustworthy partnerships that foster improved financial performance and operational confidence.

Cadara unveiled its new identity in early 2026, marking a shift towards a modern healthcare technology provider specifically catered to post-acute care environments. The transition is also a move to signify the growth the company has experienced over its 30-year history, during which it has become a trusted partner for over 1,700 post-acute organizations nationwide.

Through intelligent software and expert guidance, Cadara is committed to simplifying complex revenue operations, thus enabling organizations to navigate financial challenges effectively. As the new era with Marina Aslanyan begins, the industry watches closely to see how her leadership will influence the future landscape of healthcare technology, and by extension, the post-acute care sector as a whole.

To learn more about Cadara and its innovative solutions, visit cadara.com or follow them on LinkedIn. Cadara stands as a testament to progress in healthcare technology, ensuring that customer needs remain central to its mission in this evolving industry.